vs
Privia Health Group, Inc.（PRVA）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是Privia Health Group, Inc.的1.7倍（$906.4M vs $541.2M），Rollins, Inc.净利率更高（11.9% vs 1.7%，领先10.2%），Privia Health Group, Inc.同比增速更快（17.4% vs 10.2%），过去两年Privia Health Group, Inc.的营收复合增速更高（14.2% vs 0.8%）
Privia Health Group, Inc.是总部位于美国的医疗科技与服务企业，为独立诊所、医疗系统和医疗支付方提供价值导向型医疗解决方案，涵盖人群健康管理、患者互动平台、护理协调支持及行政流程优化工具，助力提升诊疗效果、降低医疗参与方运营成本。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
PRVA vs ROL — 直观对比
营收规模更大
ROL
是对方的1.7倍
$541.2M
营收增速更快
PRVA
高出7.2%
10.2%
净利率更高
ROL
高出10.2%
1.7%
两年增速更快
PRVA
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $541.2M | $906.4M |
| 净利润 | $9.2M | $107.8M |
| 毛利率 | — | — |
| 营业利润率 | 2.1% | 16.1% |
| 净利率 | 1.7% | 11.9% |
| 营收同比 | 17.4% | 10.2% |
| 净利润同比 | 108.0% | 2.5% |
| 每股收益（稀释后） | $0.08 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRVAROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $541.2M | $912.9M | ||
| Q3 25 | $580.4M | $1.0B | ||
| Q2 25 | $521.2M | $999.5M | ||
| Q1 25 | $480.1M | $822.5M | ||
| Q4 24 | $460.9M | $832.2M | ||
| Q3 24 | $437.9M | $916.3M | ||
| Q2 24 | $422.3M | $891.9M |
净利润PRVAROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $9.2M | $116.4M | ||
| Q3 25 | $6.9M | $163.5M | ||
| Q2 25 | $2.7M | $141.5M | ||
| Q1 25 | $4.2M | $105.2M | ||
| Q4 24 | $4.4M | $105.7M | ||
| Q3 24 | $3.5M | $136.9M | ||
| Q2 24 | $3.5M | $129.4M |
营业利润率PRVAROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 2.1% | 17.5% | ||
| Q3 25 | 2.5% | 21.9% | ||
| Q2 25 | 0.6% | 19.8% | ||
| Q1 25 | 1.1% | 17.3% | ||
| Q4 24 | 1.1% | 18.1% | ||
| Q3 24 | 1.3% | 20.9% | ||
| Q2 24 | 1.2% | 20.4% |
净利率PRVAROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | 1.7% | 12.8% | ||
| Q3 25 | 1.2% | 15.9% | ||
| Q2 25 | 0.5% | 14.2% | ||
| Q1 25 | 0.9% | 12.8% | ||
| Q4 24 | 1.0% | 12.7% | ||
| Q3 24 | 0.8% | 14.9% | ||
| Q2 24 | 0.8% | 14.5% |
每股收益（稀释后）PRVAROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $0.08 | $0.24 | ||
| Q3 25 | $0.05 | $0.34 | ||
| Q2 25 | $0.02 | $0.29 | ||
| Q1 25 | $0.03 | $0.22 | ||
| Q4 24 | $0.03 | $0.22 | ||
| Q3 24 | $0.03 | $0.28 | ||
| Q2 24 | $0.03 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $479.7M | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $737.2M | $1.4B |
| 总资产 | $1.4B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资PRVAROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $479.7M | $100.0M | ||
| Q3 25 | $441.4M | $127.4M | ||
| Q2 25 | $390.1M | $123.0M | ||
| Q1 25 | $469.3M | $201.2M | ||
| Q4 24 | $491.1M | $89.6M | ||
| Q3 24 | $422.0M | $95.3M | ||
| Q2 24 | $387.4M | $106.7M |
总债务PRVAROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PRVAROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $737.2M | $1.4B | ||
| Q3 25 | $709.1M | $1.5B | ||
| Q2 25 | $682.9M | $1.4B | ||
| Q1 25 | $659.4M | $1.4B | ||
| Q4 24 | $635.2M | $1.3B | ||
| Q3 24 | $614.9M | $1.3B | ||
| Q2 24 | $595.4M | $1.2B |
总资产PRVAROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.4B | $3.1B | ||
| Q3 25 | $1.4B | $3.2B | ||
| Q2 25 | $1.3B | $3.2B | ||
| Q1 25 | $1.2B | $2.9B | ||
| Q4 24 | $1.1B | $2.8B | ||
| Q3 24 | $1.1B | $2.8B | ||
| Q2 24 | $1.1B | $2.8B |
负债/权益比PRVAROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $127.5M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | — | $111.2M |
| 自由现金流率自由现金流/营收 | — | 12.3% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | 13.93× | 1.10× |
| 过去12个月自由现金流最近4个季度 | — | $621.1M |
8季度趋势，按日历期对齐
经营现金流PRVAROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $127.5M | $164.7M | ||
| Q3 25 | $52.0M | $191.3M | ||
| Q2 25 | $8.0M | $175.1M | ||
| Q1 25 | $-24.1M | $146.9M | ||
| Q4 24 | $74.8M | $188.2M | ||
| Q3 24 | $33.2M | $146.9M | ||
| Q2 24 | $34.5M | $145.1M |
自由现金流PRVAROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $182.8M | ||
| Q2 25 | — | $168.0M | ||
| Q1 25 | — | $140.1M | ||
| Q4 24 | — | $184.0M | ||
| Q3 24 | — | $139.4M | ||
| Q2 24 | — | $136.4M |
自由现金流率PRVAROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | — | 17.4% | ||
| Q3 25 | — | 17.8% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 22.1% | ||
| Q3 24 | — | 15.2% | ||
| Q2 24 | — | 15.3% |
资本支出强度PRVAROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 1.0% |
现金转化率PRVAROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 13.93× | 1.41× | ||
| Q3 25 | 7.58× | 1.17× | ||
| Q2 25 | 2.97× | 1.24× | ||
| Q1 25 | -5.70× | 1.40× | ||
| Q4 24 | 17.00× | 1.78× | ||
| Q3 24 | 9.38× | 1.07× | ||
| Q2 24 | 9.94× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRVA
| FFS Patient Care | $364.4M | 67% |
| Capitated Revenue | $71.4M | 13% |
| Shared Savings | $46.9M | 9% |
| FFS Administrative Services | $36.0M | 7% |
| Care Management Fee PMPM | $20.0M | 4% |
| Other Revenue | $2.5M | 0% |
ROL
暂无分部数据
